Reuters logo
a year ago
BRIEF-Zealand Pharma: royalty revenue of DKK 6.4 mln in Q2 on sales of Lyxumia
July 29, 2016 / 5:46 AM / a year ago

BRIEF-Zealand Pharma: royalty revenue of DKK 6.4 mln in Q2 on sales of Lyxumia

July 29 (Reuters) - Zealand Pharma A/S :

* Lixisenatide as adlyxin to treat type 2 diabetes commercial launch by Sanofi in U.S. is expected later in H2

* Royalty revenue of 6.4 million Danish crowns ($950,000)/0.9 million euros in Q2 2016 on sales of Lyxumia(Lixisenatide outside U.S.)

* US FDA approved recently lixisenatide as adlyxinto treat type 2 diabetes Source text for Eikon:

Further company coverage: ($1 = 6.7132 Danish crowns) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below